申请人:Pfizer Inc
公开号:US20040097554A1
公开(公告)日:2004-05-20
The present invention relates to compounds of the formula (I)
1
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
7
, and L are as described in the specification. The present invention also relates to pharmaceutical compositions that include compounds of the formula (I) and a pharmaceutically acceptable carrier. Moreover, the present invention relates to methods of using the above-described compounds and compositions to treat and prevent diseases and conditions including those that may be treated or prevented by antagonizing the CCR1 receptor.
本发明涉及式(I)的化合物1,其中R1、R2、R3、R4、R5、R7和L如规范中所述。本发明还涉及包括式(I)的化合物和药学上可接受的载体的制药组合物。此外,本发明涉及使用上述化合物和组合物治疗和预防疾病和病症的方法,包括那些通过拮抗CCR1受体可以治疗或预防的疾病和病症。